Kilitch Drugs (India) Ltd Share Price Today - Kilitch Drugs (India) Ltd Stock Price Live NSE/BSE

Kilitch Drugs (India) Ltd

NSE: KILITCH BSE: 524500

₹316.10

(-0.69%)

Sun, 22 Mar 2026, 04:37 am

MTF 5xInvest in Kilitch Drugs (India) Ltd with 5x Leverage Buy with MTF

Market Cap5.51B

PE Ratio20.17

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Kilitch Drugs (India) Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
550.73
Net Profit
24.94
P/B
2.87
Sector P/E
31.86
P/E
21.77
EV/EBITDA
14.47
Debt/Equity (Industry)
0.25
Interest Cover (Industry)
11.42
ROCE (Industry)
16.55
RONW (Industry)
14.50
ROE
11.68
ROCE
15.57
Debt/Equity
0.21
EPS (TTM)
14.90
Dividend Yield
0
Book Value
151.97
Interest Cover
6.73

Analysis

all

Pros

Dividends paid are well covered by earnings (3.4x coverage).
Kilitch Drugs (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Kilitch Drugs (India) is profitable, therefore cash runway is not a concern.
Kilitch Drugs (India) is profitable, therefore cash runway is not a concern.
Debt is covered by short term assets, assets are 5.2x debt.

Cons

Dividends per share have fallen over the past 10 years.
Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
Kilitch Drugs (India)'s pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Kilitch Drugs (India)'s dividend is below the markets top 25% of dividend payers in India (3.08%).
Debt is not well covered by operating cash flow (2.2%, less than 20% of total debt).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	63.77	63.77	69.23	69.23	69.23
FII	0	0.00	0.00	0	0.00
DII	0.00	0.00	0.00	0.00	0.00
Public	36.23	36.23	30.76	30.77	30.77
Government	0	0	0	0	0

Technical Analysis

RSI

45.23

MACD

-3.68

50 DMA

327.94

200 DMA

372.08

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	536.67	441.77	382.63	346.87	287.73	251.97	157.07
Fibonacci	441.77	405.51	383.12	346.87	310.61	288.22	251.97
Camarilla	349.60	340.90	332.20	346.87	314.80	306.10	297.40

Pivots Level: Classic

+189.80

536.67

+94.90

441.77

+35.77

382.63

346.87

Pivot Point

LTP: 316.10

-59.13

287.73

-94.90

251.97

-189.80

157.07

Moving Average

SMAEMA

Period

Value

10-EMA
317.97
20-EMA
320.41
30-EMA
323.11
50-EMA
328.18
100-EMA
339.72
200-EMA
351.26

Announcement Date	Purpose	Action	Ex Date
18 Mar 2026	bonus	1:1 Bonus Issue of Equity Shares	24 Mar 2026
11 Feb 2026	egm
11 Feb 2026	board-meetings	Quarterly Results, Bonus Issue, EGM, Increase in Authorised Capital
13 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
01 Sept 2025	agm
09 Jul 2025	rights	2:23 Rights Issue of Equity Shares	15 Jul 2025
15 Jun 2025	rights	Right Issue of Equity Shares	15 Jul 2025
26 Aug 2024	agm
19 Aug 2024	agm	Annual General Meeting	20 Sept 2024
21 Aug 2023	agm	Annual General Meeting	22 Sept 2023

Kilitch Drugs (India) Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Lupin Ltd

Kilitch Drugs (India) Ltd About

Kilitch Drugs (India) in the manufacturing, supplying and marketing of broad range of pharmaceutical formulation in the various dosage from like Solid, Liquid and Parental across the globe with over three decades of experience.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1992

Headquarters

CEO

Mukund P Mehta

Employees

Contact

Website

http://www.kilitch.com

info@kilitch.com

Phone

91-022-27670322/27680913/65144185

Location

C-301/2 MIDC TTC Indl Area, Pawane Village, Thane, Maharashtra, 400705

Year	History
2009	The Company received a GOLD AWARD for Quality Excellence.
2010	The Company's Equity Shares were listed at NSE.
2011
2015	Kilitch Drugs entered a joint venture with a local firm in Ethiopia.
2021	Kilitch Drugs started production of Cephalosporins Injectables at Ethiopia Plant on 26th July.

Client Name	Order Side	QTY	Avg Price	Date
SHRENI SHARES PVT	Sell	117495	405.58	28 Oct 2025
SHRENI SHARES PVT	Buy	32332	401.82	28 Oct 2025
SHAH DIPAK KANAYALAL	Sell	66699	96.35	06 Mar 2018
BP FINTRADE PRIVATE LIMITED	Buy	78214	96.36	06 Mar 2018
BP FINTRADE PRIVATE LIMITED	Sell	56811	98.98	06 Mar 2018
SHAH DIPAK KANAYALAL	Sell	80000	115.88	01 Mar 2018
RONAK BANSAL	Sell	72184	131.28	27 Feb 2018
RONAK BANSAL	Buy	72184	122.9	27 Feb 2018
ANKUR TUKARAM MAYEKAR	Buy	150200	85.23	22 Jan 2018
ARUNA DINESH SHAH	Buy	150400	89.32	22 Jan 2018

Kilitch Drugs (India) Ltd News

Kilitch Drugs Holds EGM for Capital Increase & Bonus

Kilitch Drugs (India) Limited conducted an Extra-Ordinary General Meeting on March 13, 2026, to approve authorized capital increase and 1:1 bonus share issue through video conferencing.

13 Mar 2026

companies

Kilitch Drugs EGM on March 13 for Capital Increase

Kilitch Drugs (India) Limited schedules EGM for March 13, 2026 to increase authorized capital from ₹25 crore to ₹40 crore and approve 1:1 bonus share issue.

16 Feb 2026

co actions results

Kilitch Drugs Submits Q3FY26 Monitoring Report

Kilitch Drugs (India) Limited submitted its monitoring agency report for Q3FY26 under SEBI regulations, showing Rs. 22.05 crore utilization towards Greenfield project with no deviations reported.

13 Feb 2026

co actions results

Kilitch Drugs Reports No Deviation in Rights Issue Fund Utilization for Q2 FY26

Kilitch Drugs (India) Limited's monitoring agency report for the quarter ended September 30, 2025, confirms no deviation in the utilization of Rs. 49.92 crore raised through rights issue. The company utilized Rs. 18.30 crore towards its Greenfield project at Pen, Maharashtra, and Rs. 0.61 crore for general corporate purposes, with remaining funds invested in fixed deposits.

15 Nov 2025

corporate action

Kilitch Drugs Reports 18% Jump in H1FY26 Profit to ₹10.30 Crore

Kilitch Drugs Limited announced an 18.1% increase in Profit After Tax to ₹10.30 crore for H1FY26, up from ₹8.72 crore in H1FY25, driven by improved operational efficiencies and better product mix. The pharmaceutical company also reported 14.23% growth in total income to ₹101.28 crore and completed a rights issue of ₹49.92 lakh to fund its upcoming Greenfield project at Pen.

14 Nov 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800